<DOC>
	<DOCNO>NCT00916617</DOCNO>
	<brief_summary>This study evaluate safety tolerability bapineuzumab administer subcutaneous injection . The study open subject participate precede double-blind study ( 3133L1-2203 US ) . Subjects receive weekly injection bapineuzumab 3 year ( 156 dos ) . One dosage level include : 5 mg/week . All subject receive active treatment ( bapineuzumab ) subject receive placebo .</brief_summary>
	<brief_title>Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis probable Alzheimer disease Completed preceding doubleblind study ( 3133L12203 US ) MMSE score &gt; 9 . Significant brain MRI abnormalities Clinically important psychiatric symptom History stroke</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>open-label</keyword>
	<keyword>safety</keyword>
	<keyword>antibody</keyword>
</DOC>